FDA advises restricting use of fluoroquinolone antibacterial drugs

The U.S. Food and Drug Administration (FDA) is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections. An FDA safety review has shown that fluoroquinolones, when used systemically (i.e. tablets, capsules, and injectable), are associated with disabling and potentially permanent serious side effects that can occur together. These side effects can involve the tendons, muscles, joints, nerves, and central nervous system. The agency recommends that healthcare professionals stop systemic fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course. Read the FDA safety announcement.